Brusalis Christopher M, Weissman Alexander C, Yazdi Allen A, Muth Sarah A, Allahabadi Sachin, Cole Brian J
Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois, USA.
Video J Sports Med. 2024 Apr 11;4(2):26350254231212928. doi: 10.1177/26350254231212928. eCollection 2024 Mar-Apr.
The proximal humerus is the second-most common anatomic site for osteonecrosis, a condition of disrupted blood supply leading to death of bone tissue, with resultant shoulder pain and dysfunction. Core decompression is a viable joint-preserving surgical intervention that aims to improve local blood supply and restore bone health prior to bony collapse.
Humeral head osteonecrosis has numerous underlying causes, most commonly the sequelae of prior trauma, chronic use of systemic corticosteroids, sickle cell disease, and alcohol abuse. Core decompression may be indicated in the early, pre-collapse stages of osteonecrosis, whereas more advanced stages of disease are commonly indicated for joint reconstruction procedures, such as bone grafting or arthroplasty.
With the patient in the beach chair position, bone marrow aspirate concentrate (BMAC) is harvested through a percutaneous incision along the anterolateral proximal humerus. While viewing through a standard posterior portal, a transtibial anterior cruciate ligament (ACL) guide is placed through an anterior portal at a site on the humeral head surface, centered at the area of greatest humeral head bone edema as identified on preoperative magnetic resonance imaging. A guide pin is placed through a lateral portal within the ACL guide, to the subchondral bone. A 7.0-mm reamer is applied over the guidewire, followed by administration of demineralized bone matrix soaked in BMAC into the reamed channel within the proximal humerus.
In patients with early stages of humeral head osteonecrosis, core decompression confers superior clinical outcomes with reduced rates of subsequent surgical procedures compared with nonoperative treatment. Core decompression has shown to reduce the radiographic progression of osteonecrosis. Further research is necessary to determine the additional clinical benefits of augmentation with orthobiologic agents, such as BMAC.
Arthroscopic-assisted core decompression is a valuable, minimally invasive surgical treatment for early-stage proximal humerus osteonecrosis. Adjunctive treatment with BMAC and demineralized bone matrix may enhance clinical outcomes.
The author(s) attests that consent has been obtained from any patient(s) appearing in this publication. If the individual may be identifiable, the author(s) has included a statement of release or other written form of approval from the patient(s) with this submission for publication.
肱骨近端是骨坏死第二常见的解剖部位,骨坏死是一种血液供应中断导致骨组织死亡的病症,会引起肩部疼痛和功能障碍。髓芯减压是一种可行的保关节手术干预措施,旨在改善局部血液供应并在骨质塌陷前恢复骨骼健康。
肱骨头骨坏死有多种潜在病因,最常见的是既往创伤后遗症、长期使用全身性皮质类固醇、镰状细胞病和酗酒。髓芯减压适用于骨坏死的早期、塌陷前阶段,而疾病的更晚期通常适用于关节重建手术,如骨移植或关节成形术。
患者处于沙滩椅位时,通过沿肱骨近端前外侧的经皮切口采集骨髓抽吸浓缩物(BMAC)。通过标准后外侧入路观察时,将经胫骨前交叉韧带(ACL)导向器通过前外侧入路放置在肱骨头表面的一个部位,以术前磁共振成像确定的肱骨头骨水肿最严重区域为中心。将导针通过ACL导向器内的外侧入路插入至软骨下骨。在导丝上应用7.0毫米扩孔钻,随后将浸泡在BMAC中的脱矿骨基质注入肱骨近端的扩孔通道内。
在肱骨头骨坏死早期患者中,与非手术治疗相比,髓芯减压可带来更好的临床效果,后续手术率降低。髓芯减压已显示可减少骨坏死的影像学进展。有必要进一步研究以确定使用BMAC等骨科生物制剂进行强化治疗的额外临床益处。
关节镜辅助下髓芯减压是早期肱骨近端骨坏死的一种有价值的微创手术治疗方法。BMAC和脱矿骨基质的辅助治疗可能会改善临床效果。
作者证明已获得本出版物中出现的任何患者的同意。如果个体可能被识别,作者已随本投稿附上患者的豁免声明或其他书面形式批准,以供发表。